

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JDH 京东健康

JD Health International Inc.

京东健康股份有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock Codes: 6618 (HKD counter) and 86618 (RMB counter))

INSIDE INFORMATION

UNAUDITED UPDATE ON THE 2026 FIRST QUARTER

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Business Update

During the first quarter of 2026, JD Health entered into strategic partnerships with several leading pharmaceutical companies, including Organon, Kenvue, CR Jiangzhong and Shouer Pharmaceutical. Notably, in collaboration with Organon, we further advanced the implementation of AI-assisted diagnosis and treatment and digital disease management across therapeutic areas such as cardiovascular, respiratory and women’s health. Meanwhile, we continued to strengthen our position as “the First Online Marketplace for New Drug Launches”. During the quarter, JD Health introduced over 30 new drugs, including Novartis’ Phapsido[®], the world’s first globally approved oral targeted therapy indicated for chronic spontaneous urticaria, as well as Lumirix[®], the first-ever prescription treatment approved by China NMPA for vitiligo repigmentation.

During the first quarter of 2026, we deepened the integration of “AI Jingyi,” our AI medical assistant tailored for users, across the “Consultation + Examination + Diagnosis + Pharmaceutical” closed-loop service model. “AI Jingyi” not only provides professional guidance in response to users’ health-related inquiries, but also directly connects users to an integrated suite of services, including online consultations, at-home rapid testing, home care on-demand service, and medication fulfillment through JD Pharmacy, forming a comprehensive, end-to-end service ecosystem. The number of users consulting the AI agent “Dr. Da Wei” (大為醫生) during the first three months of 2026 had already exceeded the full-year total in 2025.

Unaudited Financial Information

The Company is pleased to announce the unaudited revenue, operating income and profit of the Group for the three months ended March 31, 2026 together with comparative figures for the corresponding period of 2025:

	Three months ended March 31,		
	2026	2025	Change
	<i>RMB'000</i>	<i>RMB'000</i>	<i>(%)</i>
	(Unaudited)	(Unaudited)	
Revenue	19,467,548	16,645,156	17.0
Operating income ⁽¹⁾	1,824,693	1,071,013	70.4
Non-IFRS operating income ⁽²⁾	1,936,471	1,308,356	48.0
Profit for the period	1,664,985	934,358	78.2
Non-IFRS profit for the period ⁽³⁾	1,874,052	1,767,843	6.0

- (1) Operating income consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses (including reversals of impairment losses) on financial assets.
- (2) We define “non-IFRS operating income” as operating income for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.
- (3) We define “non-IFRS profit” as profit for the period, excluding share-based payment expenses, fair value changes for financial assets at fair value through profit or loss except for wealth management products, and tax effects on non-IFRS adjustments for the period. We exclude these items because they are either non-operating in nature, or they are not indicative of our core operating results and business outlook, or do not generate any cash outflows.

The above information is based on the board (the “**Board**”) of directors (the “**Directors**”) of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

Set Up of Trust for Share Incentive Purposes

The Company will set up a trust to conduct on-market purchases of the shares of the Company for share incentive purposes. The shares purchased by the trust shall be used to satisfy the vesting of share awards and/or exercise of options granted under the share incentive schemes of the Company from time to time. The proposed use of such shares held by the trust may reduce new share issuance for satisfying grants under the share incentive schemes of the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JD Health International Inc.
Mr. Dong Cao
Executive Director

Hong Kong, May 12, 2026

As of the date of this announcement, the Board comprises Mr. Dong Cao as the executive Director, Mr. Richard Qiangdong Liu as non-executive Director, and Ms. Ling Li, Dr. Jiyu Zhang, Mr. Xingyao Chen, Mr. Ying Wu and Professor George Lau as independent non-executive Directors.